Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Inflammatory Disease
Conditions
Pelvic Inflammatory Disease
Trial Timeline
Jan 1, 2007 → May 1, 2008
NCT ID
NCT00453349About Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole is a phase 3 stage product being developed by Bayer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00453349. Target conditions include Pelvic Inflammatory Disease.
What happened to similar drugs?
3 of 5 similar drugs in Pelvic Inflammatory Disease were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00453349 | Phase 3 | Completed |
Competing Products
11 competing products in Pelvic Inflammatory Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 35 |
| BGS649 + Placebo | Novartis | Phase 2 | 27 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 35 |
| Azithromycin | Pfizer | Phase 3 | 40 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 18 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 27 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 43 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 26 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 37 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 23 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 40 |